Simple ‘metabolic reset’ found to prevent weight rebound after discontinuing GLP-1 drugs

These numbers are expected to rise as some of these drugs are starting to also become available in a pill form.

While initially developed for blood sugar control to manage diabetes, they have since become available extensively for those seeking to shed some pounds, helping patients lose anywhere from 15 per cent to 20 per cent of their body weight.

But recent studies suggest that many patients who discontinue these drugs after achieving their weight loss results are regaining nearly two-thirds of their lost pounds.

Now, a new world-first clinical trial reveals a safe, effective, and long-lasting way to maintain drug-free weight loss after GLP-1 discontinuation, scientists say.

"As effective as GLP-1 medications are, many people stop taking them because of cost, side effects or simply not wanting to take a drug long-term," said Dr Shelby Sullivan from the Dartmouth Geisel School of Medicine.

“But, if they stop these medications, weight regain occurs in the vast majority of patients, and the metabolic benefits are lost,” Dr Sullivan explained.

The new minimally invasive endoscopic procedure, known as duodenal mucosal resurfacing, may provide “lasting weight-loss maintenance”, according to scientists.

It uses targeted heat to burn the unhealthy inner mucosal lining of the duodenum, the upper part of the small intestine just below the stomach.

In the ongoing trial, scientists have been testing whether the procedure can stimulate the growth of new, healthy tissue and result in a sustained metabolic reset.

Tissues targeted by the drug are typically involved in producing hormones that are mimicked by GLP-1 drugs.

Normally, high-fat diets can lead to thickening and other changes in this tissue layer and rewire how the gut responds to food.

By rejuvenating the tissue layer, the procedure appears to reset individuals' metabolism to their new post-GLP-1 weight, scientists say.

Results from the first group of trial participants are being presented this week at Digestive Disease Week (DDW) 2026.

The study included six months of follow-up data and points to durable weight maintenance with the procedure.

Of the 45 participants included in the research, 29 underwent the endoscopic procedure, while 16 received a sham treatment.

All of the participants lost at least 15 per cent of their total weight with the GLP-1 drug tirzepatide before discontinuing the drug.

Scientists found that six months after stopping the drug, those who had the sham procedure regained 40 per cent more weight than the treatment group.

In comparison, those who underwent the procedure regained just seven pounds, maintaining over 80 per cent of their weight loss.

The weight difference between the groups also appears to be widening from one to six months post-intervention, scientists say.

"What's particularly encouraging is that the benefit appears to increase over time rather than fade, and that it behaves like a drug in terms of dose response," Dr Sullivan said, adding that the results give confidence “that we're targeting the right biology”.

"You can be back to your daily routine in about a day. Participants could not tell if they had the sham or real procedure because there are not a lot of symptoms after the procedure,” he said.